Introduction: Graves’ disease is the most common cause of hyperthyroidism. Its treatment uses synthetic antithyroid drugs but the use of aggressive radical therapy such as surgery or non-aggressive therapy such as iodine-131 is not uncommon. Treatment of Graves’ disease with radioactive iodine or iratherapy is a simple, inexpensive, well-tolerated treatment. It was introduced in Senegal in 2016. We report through this work the preliminary assessment of the only nuclear medicine service in Senegal in the management of Graves’ disease by iodine-131. Patients and Methods: Retrospective study of the first cases of Graves’ disease treated with iratherapy in Senegal. Socio-demographic, clinical, paraclinical, therapeutic and evolutionary aspects were studied. Radiation protection rules have been implemented and contraception has been effective for six months in women of childbearing age. Results: 25 patients were collected with a mean age of 45 years, twenty women (80%), a family goiter in 24% and a psycho-affective context in 64% of cases. Thyrotoxicosis syndrome was associated with goiter in 68% of patients and exophthalmos in 64%. Thyroid ultrasound performed in 20 patients showed vascular goiter in 80% and thyroid scintigraphy in 3 patients, homogeneous and diffuse hyperfixation. TRAK dosed in 8 patients was still positive. All patients had received first-line medical treatment. The average duration of this treatment was more than 18 months in 92%. The empirically used iodine-131 activity averaged 15.35 mCi. Oral corticosteroid therapy was prescribed in 7 patients for the prevention of malignant orbitopathy. No early side effects were noted. The remission rate at 3 months was 52% and at 6 months was 88% to 92%. Conclusion: The effectiveness of radioactive iodine, in particular ablative doses in the treatment of hyperthyroidism, is no longer to be demonstrated. Taking into account our socioeconomic context, iratherapy should be a treatment of choice for hyperthyroidism with a good quality/price ratio and excellent tolerance.
References
[1]
Wémeau, J.L., Klein, M., Sadoul, J.L. and Céphise, F.L. (2020) Consensus on Graves’ Disease. http://www.chu-fes.ma/endo/ftp/basdaw.pdf
[2]
Bennis, O.K. (2017) Epidemiological Profile, Clinical Profile and Management of Graves’ Disease. Master’s Thesis, Sidi Mouhamad Ben Abdallah University Faculty of Medicine and Pharmacy, Morocco.
[3]
Duran, F. (2006) Endocrinology: Goiter. Pierre and Marie Curie Faculty of Medicine.
[4]
Jacques, P. (2009) Graves’ Disease in 2009. Revue Médicale Suisse, 5, 764-768.
[5]
Ndour, O. (2014) Surgical Treatment of Graves’ Disease. Master’s Thesis. Cheikh Anta Diop University Faculty of Medicine, Pharmacy and Odonto-stomotology. Dakar.
[6]
Teissier, M.P. and Lopez, S. (2004) Dysthyroid Orbitopathy: Pathophysiology, Hormonal Balance. French Journal of Ophthalmology, 27, 806-809. https://doi.org/10.1016/S0181-5512(04)96219-5
[7]
Foulet-Rogé, A., Josselin, N., Guyetant, S., et al. (2002) Incidental Langerhans Cell Histiocytosis of Thyroid: Case Report and Review of the Literature. Endocrine Pathology, 13, 227-233. https://doi.org/10.1385/EP:13:3:227
[8]
Alaya, W., Charrada, I., Berriche, O., et al. (2017) Therapeutic and Progressive Modalities of Graves’ Disease: About 146 Patients. Annales d’Endocrinologie, 78, 326-352. https://doi.org/10.1016/j.ando.2017.07.372
[9]
Bouziane, T., Larwanou, M. and El Ouahabi, H. (2017) Predictors of Relapse of Graves’ Disease Treated with ATS: About 72 Cases. Annales d’Endocrinologie, 78, 326-352. https://doi.org/10.1016/j.ando.2017.07.370
[10]
Mbodj, M., Guerrouj, H., Amjad, I., et al. (2009) Contribution of Iodine-131 in the Treatment of Graves’ Disease in the Nuclear Medicine Department of the Ibn Sina Hospital in Rabat. Nuclear Medicine, 33, 592-598. https://doi.org/10.1016/j.mednuc.2009.07.019
[11]
Aziz Karam, M. (2014) Diagnostic and Therapeutic Strategy in the Management of Differentiated Cancers of the Thyroid Gland. Master’s Thesis, Sidi Mohammed Ben Abdallah University Faculty of Medicine and Pharmacy, Fez.
[12]
Doho Hiro, B.G. (2005) Carbimazole in the Treatment of Graves’ Disease in Côte d’Ivoire: Study of Biological Efficacy and Collateral Effects. Master’s Thesis, University of Bamako Faculty of Medicine of Pharmacy and Odonto-stomatology, Bamako.
[13]
Karam, R. (2013) Iodine-131 and Therapy for Thyroid Disorders: The Blue Pages. https://docplayer.fr/47118665-L-iode-131-et-la-therapie-des-troubles-thyroidiens.html
[14]
El Mokhtari, M., Corvo, L. and Popescu, M. (2015) Graves’ Disease about 20 Cases. Annales d’Endocrinologie, 75, 412-453.
[15]
Ben Sellem, D., Zabar, L., Dhaouadi, B., et al. (2015) Graves’ Disease: Effectiveness of Strong Iratherapy Activities. Annales d’Endocrinologie, 76, 422. https://doi.org/10.1016/j.ando.2015.07.396
[16]
El Ajmi, W., Slim, I., Rmadi, S., Yeddes, I., Krimi, S., Ltaief, B., Mhiri, A. and Ben Slimene, M.F. (2009) Evaluation of Treatment of Graves’ Disease with a Fixed Dose of Iodine-131 Nuclear Medicine. Functional and Metabolic Imaging, 33, 242.
[17]
Charfi, N., Ben Mrad, N., et al. (2005) Results of Treatment of Graves’ Disease with Radioactive Iodine (about 137 Cases). Annales d’Endocrinologie, 66, 493. https://doi.org/10.1016/S0003-4266(05)82072-4
[18]
El Yaagoubi, N., Belhaj, L., Chraïbi, A., Mouzouri, H. and Kadiri, A. (2005) Iodine-131 in Graves’ disease. Annales d’Endocrinologie, 66, 496. https://doi.org/10.1016/S0003-4266(05)82083-9
[19]
Tourari, S. (2014) Place of Iratherapy in the Treatment of Graves’ Disease: Experience of the Department of Endocrinology of the Avicenna Military Hospital Marrakech. Master’s Thesis, Cadi Ayyad University, Marrakech.
[20]
El Feleh, E., Bchir, N., Jaidane, A., et al. (2017) Clinical and Paraclinical Profile of Graves’ Disease. Annales d’Endocrinologie, 78, 326. https://doi.org/10.1016/j.ando.2017.07.352
[21]
Diagne, N., Faye, A., Ndao, A.C., et al. (2016) Epidemiological, Clinical, Therapeutic and Progressive Aspects of Graves’ Disease in Internal Medicine at Le Dantec Dakar University Hospital (Senegal). The Pan African Medical Journal, 25, Article 6. https://doi.org/10.11604/pamj.2016.25.6.7868
[22]
Joubij, M., El Aziz, S., Chadli, A., et al. (2012) Iratherapy in Graves’ Disease. The Experience of the Endocrinology Department of the CHU Ibn Rochd: About 103 Cases. Annales d’Encronilogie, 73, 301 p.
[23]
Leung, A.M. and Braverman, L.E. (2014) Consequences of Excess Iodine. Nature Reviews Endocrinology, 10, 136-142. https://doi.org/10.1038/nrendo.2013.251
[24]
French Society of Nuclear Medicine and Molecular Imaging (SFMN): Working Group (2006) Endocrine Surgery Nuclear Medicine Endocrinology. Guide for Writing Protocols for the Treatment of Hyperthyroidism with Iodine-131, 1-19.
[25]
Schlienger, J.L., Goichot, B. and Grunenberger, F. (1997) Iodine and Thyroid Function. La Revue de Médecine Interne, 18, 709-716. https://doi.org/10.1016/S0248-8663(97)83750-2
[26]
Bouziane, T., Belmahi, N. and El Ouahabi, H. (2017) Graves’ Disease in Humans: Clinical and Therapeutic Features. Annals of Endocrinology, 48, 326-352.
[27]
Morax, S. and Badelon, I. (2009) Exophtalmie Basedowienne. Journal Français d’Ophtalmologie, 32, 589-599. https://doi.org/10.1016/j.jfo.2009.09.001
[28]
El Issami, S., Sarroukh, F., Elrhoul, M., Guerrouj, H., Ghfir, I. and Ben Rais Aouad, N. (2011) Treatment of Hyperthyroidism with Iodine-131: About 280 Cases. Nuclear Medicine, 35, 528-532. https://doi.org/10.1016/j.mednuc.2011.08.001
[29]
Alaya, W., Charrada, I., Berriche, O., et al. (2017) Therapeutic and Progressive Modalities of Graves’ Disease: About 146 Patients. Annals of Endocrinology, 78, 326-352.
[30]
Oueslati, I., Belhadj Hassen, H., et al. (2015) Radioactiveiode in the Treatment of Graves’ Disease. Annals of Endocrinology, 76, 414.
[31]
Oueslati, I., Melki, A., Khessairi, N., et al. (2015) Evaluation of Basdowian Exopthalmia after Treatment with Radioactive Iodine. Annales d’Endocrinologie, 75, 353-357.
[32]
Hebaili, N., El Bez, L., Ben Sellem, D., et al. (2013) Evolution of Exophthalmos Basedowienne after Iratherapy: Impact of Corticosteroid Therapy. Annales d’Endocrinologie, 74, 349. https://doi.org/10.1016/j.ando.2013.07.373
[33]
Fieffe, S., et al. (2009) Traitement des Hyperthyroïdies par l’iode 131: Dose calculée versus dose fixeTreatment of Hyperthyroidism by 131-Iodine. Nuclear Medicine, 33, 313. https://doi.org/10.1016/j.mednuc.2009.02.008
[34]
Bennour, M., Rojbi, I., Rezgani, I., et al. (2017) Graves’ Disease: Therapeutic and Evolutionary Aspects. Annales d’Endocrinologie, 78, 326-352.
[35]
El Feleh, E., Mahjoubi, S., Bchir, N., et al. (2017) Place of Iratherapy in the Treatment of Graves’ Disease Thyroid. Annals of Endocrinology, 78, 326. https://doi.org/10.1016/j.ando.2017.07.352
[36]
Boumelit, A., Zemalech, A., Mehjahdi, A., et al. (2017) The Contribution of Iodine-131 in the Treatment of Graves’ Disease. About 71 Cases. Nuclear Medicine, 41, 207-208. https://doi.org/10.1016/j.mednuc.2017.02.193
[37]
Aschawa, H., Touil, S., Shimi, Y., et al. (2017) Hyperthyroidism: Short-Term Effectiveness of Radioactive Iodine Treatment. Moroccan Journal of Public Health, 4, 7-12.
[38]
El Yaagoubi, N., Belhaj, L., Chraïbi, A., et al. (2005) Iodine-131 in Graves’ Disease. Annales d’Endocrinologie, 66, 496 p.
[39]
Dejax, C., Vennat, J.C.I. and De Freitas, D. (2005) Treatment of Hyperthyroidism in the Elderly with Iodine-131. About 180 Patients. Radiation Protection and Waste Management Problems Related to Iodine-131 Treatment. Médecine Nucléaire et Imagerie Fonctionnelle, 29, 609-619.
[40]
Hebaili, N., El Bez, I., Ben Sellem, D., et al. (2014) Hypothyroidism Post-Metabolic Iodine Radiation Therapy. Annales d’Endocrinologie, 75, 488. https://doi.org/10.1016/j.ando.2014.07.740
